β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer

Programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) checkpoint blocking antibodies have been shown to be a powerful immune checkpoint blockade (ICB) therapy for patients with cancer. However, patients quickly develop resistance to immunotherapy. β-glucan, an immune adjuvant, has been found to stimulate in...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Mengjie Wang, Yu Bai, Jiaxin Pei, Dongqing Li, Xiaolin Pu, Wenyu Zhu, Lei Xia, Chunjian Qi, Hua Jiang, Yongling Ning
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2022-04-01
סדרה:Frontiers in Pharmacology
נושאים:
β-Glucan
PD-1
PD-L1
immune checkpoint blockade therapy
resistance
גישה מקוונת:https://www.frontiersin.org/articles/10.3389/fphar.2022.887457/full
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים